New Report Just Published: Global Botulinum Toxin

NEW YORK--(Business Wire)--
Reportlinker.com just added a new market research report to its catalogue.

Global Botulinum Toxin Market

http://www.reportlinker.com/p0119494/World-Botulinum-Toxin-Market.html?utm_source=BizWire&utm_medium=PR&utm_campaign=BizWire

This report analyzes the worldwide markets for Botulinum Toxin in Millions of
US$.

The Study Analyzes the Market for `Botulinum Toxin` by the Following Segments:
Cosmetic, and Therapeutic (Movement Disorders/Pain, Headache, Hyperhidrosis,
Overactive Bladder, & Spasticity)

The report provides separate comprehensive analytics for the USA, Japan, Europe,
and Rest of World. Annual forecasts are provided for each region for the period
of 2000 through 2015.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data
Interpretation & Reporting Level I-2 Product Definitions and Scope of Study I-3
Cosmetic Applications I-3 Therapeutic Applications I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1 A Prelude II-1 Botulinum Toxin: "The Science, The
Hopes & the Risks" II-1 Future Opportunities Span Beyond The Developed Markets
II-2 A Peek Into Noteworthy Trends & Issues II-2 Changing Consumer Sentiments
II-2 Aging Population: A Weighty Demographic Driver II-3 Unmet Medical Needs
Encourage Off-Label Use: A Cause for Concern or Jubilation? II-3 Need for
Physician Education Rises With Growing Off Label Usage II-3 High Voltage Ad
Campaigns Boost Patient Awareness II-4 Societal Pressure to Look Young Drives up
Demand for Facial Aesthetics II-4 Cosmetic Botulinum Toxin to Feel the Pinch of
the Recession II-4 Financing of Non-Reimbursed Healthcare: The Need of the Hour
II-5 Combination Therapies: A Double Whammy Success II-5 Short Lived Aesthetic
Effects: A Strong Business Case for Revision Treatments II-6 Consolidation Blows
in the Aesthetic Healthcare Industry II-6 Undesirable Side Effects: A Challenge
to Reckon With II-6 Immunogenicity Undermines Patient Compliance II-7 Stringent
Regulations Delay Market Approval & Put Reimbursements in Limbo II-7
Non-Injectable Alternatives to Turn On the Heat II-7 Fears of Terrorism &
Biological Warfare Thwart International Trade II-8 Competition II-8 Allergan
Wields the Scepter II-8

Table 1: Revenues of Allergan, Inc (2006 & 2007): Breakdown of Net Sales of
Botox/Neuromodulator and Total Revenues (In US$ Million) II-9

Table 2: European Market for Non-Surgical Cosmetic Procedures (2006): Percentage
Share Breakdown of Revenues by Leading Players -Allergan, Q-Med, Mentor
Corporation, Mattioli Engineering, Candela, and Others (includes corresponding
Graph/Chart) II-9

Table 3: European Market for Non-Surgical Cosmetic Procedures (2009): Percentage
Breakdown of Revenues by Type of Procedure -Cosmetic Botulinum Toxin Injections,
Facial Fillers, Microdermabrasion, Chemical Peeling, and Aesthetic Lasers
(includes corresponding Graph/Chart) II-10 Reloxin Emerges to Threaten
Allergan`s Dominance II-10 Reloxin Vs Botox: A Comparison II-10 Outlook for
Allergan`s Botox II-11 Market Share Statistics: The New Batting Order II-12
Global II-12

Table 4: World Market for Therapeutic Neurotoxins (2008): Percentage Breakdown
of Revenues by Company/Brand -Botox (Allergan), Dysport (Ispen), Myobloc
(Solstice), and Others (includes corresponding Graph/Chart) II-12

Table 5: World Market for Cosmetic Neurotoxins (2008): Percentage Breakdown of
Revenues by Company/Brand - Botox/Vistabel (Allergan) and Dysport/Reloxin
(Ipsen/Medicis) II-12 Europe II-13

Table 6: European Market for Cosmetic Neurotoxins (2008): Percentage Breakdown
of Revenues by Company/Brand - Botox/Vistabel (Allergan) and Dysport (Ipsen)
II-13

Table 7: European Market for Therapeutic Neurotoxins (2008): Percentage
Breakdown of Revenues by Company/Brand - Botox (Allergan), Dysport (Ispen), and
Others (includes corresponding Graph/Chart) II-13 United States II-13

Table 8: US Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of
Revenues by Company/ Brand -Botox (Allergan) and Myobloc (Solstice) II-13 Market
Share Statistics: Through the Looking Glass: Year 2012 II-14 Global II-14

Table 9: World Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown
of Revenues by Company/ Brand -Botox (Allergan), Dysport (Ispen), Myobloc
(Solstice), Puretox (Mentor), Xeomin (Merz), and Others (includes corresponding
Graph/Chart) II-14

Table 10: World Market for Cosmetic Neurotoxins (2012P): Percentage Breakdown of
Revenues by Company/Brand -Botox (Allergan), Dysport/Reloxin (Ipsen/Medicis),
Xeomin (Merz), and Puretox (Mentor) (includes corresponding Graph/Chart) II-14
United States II-14

Table 11: US Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of
Revenues by Company/Brand -Botox (Allergan), Myobloc (Solstice), Dysport
(Ispen), Puretox (Mentor) and Xeomin (Merz) (includes corresponding Graph/Chart)
II-14

Table 12: US Market for Cosmetic Neurotoxins (2008 & 2012P): Percentage
Breakdown of Revenues by Company/ Brand - Botox (Allergan), Reloxin (Medicis),
and Puretox (Mentor) (includes corresponding Graph/Chart) II-15 Europe II-15

Table 13: European Market for Therapeutic Neurotoxins (2012P): Percentage
Breakdown of Revenues by Company/Brand - Botox (Allergan), Dysport (Ispen),
Xeomin (Merz) and Neurobloc (Solstice) (includes corresponding Graph/Chart)
II-15 A Peek Into Products Approved & In Pipeline II-16 New Treatment
Indications for Botulinum Toxin Compounds/ Brands in Pipeline As of the Year
2008 II-16 List of Botulinum Toxin Products/Brands that are Approved for Various
Cosmetic Therapeutic Indications As of the Year 2007 II-17

2. Product Overview II-18 Botulinum Toxin: A Poison That Cures II-18 Structure &
Mechanism of Action II-18 Disadvantages II-19 Classification of Botulinum Toxin
II-19 Botulinum Toxin Type A II-19 Historical Timeline of Botulinum Toxin:
1885-2002 II-20 Botox II-20 Key Characteristics of Botox and Botox Cosmetic
II-21 Approvals and Indications of Botox in Select Regions II-21 Common Adverse
Reactions with Botox II-22 Dysport/ Reloxin II-22 Key Characteristics of Dysport
II-22 PurTox II-23 Key Characteristics of PurTox II-23 Xeomin/ NT-201 II-23 Key
Characteristics of Xeomin/ NT-201 II-23 Botulinum Toxin Type B II-23
Myobloc/NeuroBloc II-24 Key Characteristics of Myobloc II-24 Applications of
Botulinum Toxin II-24 Cosmetic Applications II-24 Glabellar Lines II-25 Facial
Wrinkles II-25 Key Cosmetic Indications for Botulinum Toxin II-25 Therapeutic
Applications II-26 Movement Disorders/Pain II-26 Cervical Dystonia II-26
Hemifacial Spasm II-26 Blepharospasm II-26 Strabismus II-26 Chronic Pain II-27
Botox in Migraine Treatment II-27 Hyperhidrosis II-28 Bladder Dysfunctions II-28
Spasticity II-28 Other Applications II-28

3. Recent Industry Activity II-30 Johnson & Johnson Acquires Mentor Corporation
II-30 Azzalure Gains Approval from 15 European Countries II-30 Inclusion of New
Side Effect in Botox and Botox Cosmetic Labels II-30 Azzalure Gains Approval for
Aesthetic Application in the UK II-31 BioForm Medical Acquires Advanced Cosmetic
Intervention II-31 Galderma to Acquire CollaGenex II-31 Allergan and Clinique
Form Strategic Collaboration II-32 Ipsen and Medicis File BLA for Reloxin II-32
Allergan and Clinique Launch New Skin Care Products II-32 FDA Accepts Ipsen's
Filing for Reloxin II-32 GlaxoSmithKline Gains Approval for BOTOX in Japan II-32
Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product II-32
Allergan Commences Botox Study for Urological Cases in India II-33 FDA Accepts
BLA Filing for Dysport in Cervical Dystonia Cases II-33 Allergan Successfully
Completes Analysis of Two Phase III Trials for BOTOX II-33 Allergan to Set Up a
New Subsidiary in India II-33 Allergan Join Hands with India-Based Kaya II-34
Q-Med and Medy-Tox Cancel the Collaboration Agreement II-34 Galderma to Increase
Awareness in Brazil II-34 Allergan to Launch New Products in India II-34
Allergan to Establish a State-of-the-Art Botox Training Institute II-34 Q-Med
Inks a Distribution Agreement with Medy -Tox II-35 Q-Med Collaborates with
Medy-Tox for a Range of Joint Activities II-35 Medicis Plans Investment in
Revance II-35 Galderma Receives Distribution Rights for Dysport (R) II-35
Allergan to Acquire Espirit Pharma II-36 Allergan Launches "Project: Sweat Free"
II-36 Solstice Neurosciences Inks Commercialization Agreement II-36 Ipsen
Partners with Galderma II-36 Bio-Med Unveils BOTOGenie II-36 Medicis Launches
PERLANE II-36 Studies Underway for Botulinum Toxin Usage for Enlarged Calf
Muscles II-37 FDA to Assess Reloxin for Cosmetic Use II-37 Ipsen Inks
Development and Distribution Agreement with Medicis II-37 Allergan Rolls Out New
Division with Acquisition of Inamed II-37 FTC Mandates Allergan Divest Rights to
Reloxin II-37 Medicis Inks Agreement with Ipsen II-38 Solstice Neurosciences
Inks Licensing Agreement with DreamPharma II-38 Botox Enters India Market II-38
Mentor Begins Phase-I Clinical Trial on Botulinum Toxin II-38 Allergan Inks
Agreement with GlaxoSmithKline II-39 DOR BioPharma Inks Agreement with Dowpharma
II-39 Merz Pharma Receives Approval for Botulinum Toxin Type A II-39 Mentor
Initiates Phase-I Clinical Trial II-39 Mentor Establishes New Production
Facility II-39 DOR BioPharma and Thomas Jefferson University Teams-Up with US
Army II-40 Mentor Inks Licensing Agreement with WARF II-40 Solstice Acquires
World Rights for Myobloc II-40 Inamed Rolls Out Reloxin Brand II-40

4. Focus on Select Key Players II-41 Allergan, Inc (USA) II-41 Ipsen Group
(France) II-42 Lanzhou Institute of Biological Products (China) II-42
Metabiologics Inc, (USA) II-43 Merz Pharmaceuticals GmbH (Germany) II-43 Mentor
Corporation (USA) II-43 Medy-Tox Incorporated (South Korea) II-43 Medicis
Pharmaceutical Corporation (USA) II-44 Solstice Neurosciences, Inc. (USA) II-44

5. Global Market Perspective II-45

Table 14: World Recent Past, Current & Future Analysis for Botulinum Toxin by
Geographic Region/Country - US, Europe and Rest of World Independently Analyzed
by Annual Sales in US$ Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-45

Table 15: World 10-Year Perspective for Botulinum Toxin by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the
Years 2006, 2009 & 2015 (includes corresponding Graph/Chart) II-45

Table 16: World Recent Past, Current & Future Analysis for Botulinum Toxin in
Cosmetic Applications by Geographic Region - US, Europe and Rest of World
Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through
2015 (includes corresponding Graph/Chart) II-46

Table 17: World 10-Year Perspective for Botulinum Toxin in Cosmetic Applications
by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and
Rest of World for the Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-46

Table 18: World Recent Past, Current & Future Analysis for Botulinum Toxin in
Therapeutic Applications by Geographic Region - US, Europe and Rest of World
Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through
2015 (includes corresponding Graph/Chart) II-47

Table 19: World 10-Year Perspective for Botulinum Toxin in Therapeutic
Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US,
Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-47

Table 20: Global Recent Past, Current & Future Analysis for Botulinum Toxin in
Therapeutic Application by Disease Indication - Movement Disorders/Pain,
Headache, Hyperhidrosis, Overactive Bladder and Spasticity Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-48

Table 21: World 10-Year Perspective for Botulinum Toxin in Therapeutic
Application by Disease Indication - Percentage Breakdown of Dollar Sales for
Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and
Spasticity for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
II-48

III. MARKET

1. The United States III-1 A.Market Analysis III-1 Outlook III-1 Cosmetic
Procedures: An Overview III-1 Botox Leads the US Botulinum Toxin Market III-2
Botox Approvals and Indications in the US III-2 Market Dynamics III-2 Booming
Non-Surgical Treatments III-2 Aging Baby Boomers Drive Aesthetic Business III-2
Expanding Physician Base Extends Impetus to Growth III-3 Demand for Professional
Help On the Rise III-3 Direct-to-Consumer Advertising Drive Cosmetic Botulinum
Toxin III-3 Medical Spas - Growing in Number III-3 Botulism Poisoning: A Major
Concern III-4 Botox Injection - Popular Non-Invasive Cosmetic Procedure III-4

Table 22: Number of Botox Injections (2000-2005) (includes corresponding
Graph/Chart) III-4

Table 23: Botox Injections by Gender (2004) III-4

Table 24: Botox Injections by Age Group (2004) (includes corresponding
Graph/Chart) III-5 Botox Attracts American Men III-5

Table 25: Non-Invasive Cosmetic Procedures in the US (2005): Percentage of
Patients Treated by All US-Based AACS Members Practices (includes corresponding
Graph/Chart) III-5

Table 26: Cosmetic Procedures (Surgical/ Non-Surgical) in the US (2005):
Percentage of Patients Treated by All US-Based AACS Members Practices III-6 US
Cosmetic Market - Statistical Data III-6

Table 27: Cosmetic Market in the US (2004 & 2005): Leading Surgical Procedures
(includes corresponding Graph/Chart) III-6

Table 28: Cosmetic Market in the US (2004 & 2005): Leading Non-Surgical
Procedures (includes corresponding Graph/ Chart) III-7

Table 29: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown
by Gender III-7

Table 30: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown
by Age Group (includes corresponding Graph/Chart) III-7

Table 31: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown
by Facility (includes corresponding Graph/Chart) III-8

Table 32: Cosmetic Market in the US (2004): Percentage Breakdown by Procedure
Type III-8 Strategic Corporate Developments III-8 Key Players III-14 B.Market
Analytics III-17

Table 33: US Recent Past, Current & Future Analysis for Botulinum Toxin by
Application - Cosmetic Applications and Therapeutic Applications (Movement
Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity)
Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006
through 2015 (includes corresponding Graph/Chart) III-17

Table 34: US 10-Year Perspective for Botulinum Toxin by Application - Percentage
Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications
(Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and
Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
III-18

2. Europe III-19 A.Market Analysis III-19 Outlook III-19 European Market - A
Primer III-19 Botox Approvals and Indications in Select European Countries
III-19 Botox to Support Radiation Treatments III-19 Strategic Corporate
Developments III-20 Key Players III-20 B.Market Analytics III-21

Table 35: European Recent Past, Current & Future Analysis for Botulinum Toxin by
Application - Cosmetic Applications and Therapeutic Applications (Movement
Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity)
Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006
through 2015 (includes corresponding Graph/Chart) III-21

Table 36: European 10-Year Perspective for Botulinum Toxin by Application -
Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic
Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive
Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) III-22

3. Rest of World III-23 A.Market Analysis III-23 Outlook III-23 Asia III-23
India - An Emerging Market for Botox III-23 South Korea III-23

Table 37: Leading Players in the Korean Botulinum Toxin Market (2008):
Percentage Breakdown of Sales for Medy-Tox, Allergan, Ipsen, and Lanzhou
Institute (includes corresponding Graph/Chart) III-23 Australia - A Well
Supported Market III-24 Botox Approvals and Indications in Select Asian
Countries III-24 Botox Approvals and Indications in Select Latin American
Regions III-24 Botox Approvals and Indications in Other Select Global Regions
III-25 Strategic Corporate Developments III-25 Key Players III-28 B.Market
Analytics III-29

Table 38: Rest of World Recent Past, Current & Future Analysis for Botulinum
Toxin by Application - Cosmetic Applications and Therapeutic Applications
(Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and
Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for
the Years 2006 through 2015 (includes corresponding Graph/Chart) III-29

Table 39: Rest of World 10-Year Perspective for Botulinum Toxin by Application -
Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic
Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive
Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) III-30

IV. COMPETITIVE LANDSCAPE

The report profiles 19 companies including many key and niche players worldwide
such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products,
Metabiologics, Inc., Metabiologics Inc., Merz Pharmaceuticals GmbH, Mentor
Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and
Solstice Neurosciences, Inc. Market data and analytics are derived from primary
and secondary research. Company profiles are mostly extracted from URL research
and reported select online sources.

Global Botulinum Toxin Market

http://www.reportlinker.com/p0119494/World-Botulinum-Toxin-Market.html?utm_source=BizWire&utm_medium=PR&utm_campaign=BizWire

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009